Investment Thesis
Nephros demonstrates strong gross margins (57.4%) and solid 32.7% revenue growth in medical devices, with an fortress-like balance sheet (4.55x current ratio, 0.01x debt/equity). However, negative operating cash flow of -1.7M despite accounting profitability signals serious quality of earnings concerns, while extremely thin operating margins (1.9%) and minimal capital returns (ROE 1.3%) indicate the company must demonstrate significant operational improvement and cash flow conversion to justify investment at this small 5.2M revenue scale.
Strengths
- Excellent gross margins at 57.4% indicating strong product pricing power and market fit
- Fortress balance sheet with 4.0M cash, 4.55x current ratio, and negligible debt (0.01x leverage)
- Solid top-line growth of 32.7% YoY despite small revenue base in medical device sector
Risks
- Critical red flag: negative 1.7M operating cash flow despite 140K net income suggests working capital stress or earnings quality issues requiring immediate investigation
- Severe operating leverage problem with only 1.9% operating margin and minimal capital returns (ROE 1.3%, ROA 1.0%) indicating nearly all gross profit consumed by operating expenses
- Extremely small revenue base (5.2M annually) with uncertain path to sustainable profitability; cash runway of ~2.4 years at current burn rate
Key Metrics to Watch
- Operating cash flow conversion - must achieve positive OCF within next 2-3 quarters for sustainability
- Operating margin expansion and operating expense ratio as revenue scales
- Working capital management and days sales outstanding trends
Financial Metrics
Revenue
5.2M
Net Income
140.0K
EPS (Diluted)
$0.01
Free Cash Flow
-1.7M
Total Assets
13.8M
Cash
4.0M
Profitability Ratios
Gross Margin
57.4%
Operating Margin
1.9%
Net Margin
2.7%
ROE
1.3%
ROA
1.0%
FCF Margin
-33.1%
Balance Sheet & Liquidity
Current Ratio
4.55x
Quick Ratio
3.12x
Debt/Equity
0.01x
Debt/Assets
22.4%
Interest Coverage
97.00x
Long-term Debt
71.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T12:02:24.146622 |
Data as of: 2026-03-31 |
Powered by Claude AI